Pleased to share results from the CAcTUS Phase II trial of ctDNA-guided therapy in BRAF-mutant advanced melanoma are now published! 🌵🧬
CAcTUS is the first melanoma trial to adapt treatment based on ctDNA testing.
Read: www.nature.com/articles/s41...
Targeted therapy (with BRAK and MEK inhibitors) and immune checkpoint blockade have improved survival for patients with advanced BRAF-mutant cutaneous melanoma, however, the optimal scheduling for the...